SRZNW Surrozen, Inc. Stock Quote

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	-	Perf Week	-24.42%
Market Cap	-	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	30.73M	Perf Month	-24.42%
Income	-	PEG	-	EPS next Q	-	Inst Own	-	Short Float	-	Perf Quarter	-87.81%
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	-	Perf Half Y	-87.96%
Book/sh	-	P/B	-	EPS next Y	-	ROA	-	Target Price	-	Perf Year	-
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W Range	0.14 - 3.00	Perf YTD	-83.57%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-93.70%	Beta	-
Dividend %	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	34.96%	ATR	0.07
Employees	-	Current Ratio	-	Sales Q/Q	-	Oper. Margin	-	RSI (14)	37.44	Volatility	11.83% 19.28%
Optionable	No	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.00	Prev Close	0.19
Shortable	No	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	16.34K	Price	0.19
Recom	-	SMA20	-29.48%	SMA50	-73.74%	SMA200	-83.78%	Volume	0	Change	0.00%

May-16-22 08:00AM	Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel Disease (IBD) GlobeNewswire
May-11-22 08:00AM	Surrozen Reports First Quarter 2022 Financial Results GlobeNewswire -35.23%
May-05-22 08:00AM	Surrozen to Present at the BofA Securities 2022 Healthcare Conference GlobeNewswire
May-02-22 08:00AM	Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting GlobeNewswire
Mar-24-22 08:00AM	Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results GlobeNewswire -23.84%
Jan-10-22 08:00AM	Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline GlobeNewswire
Jan-05-22 08:00AM	Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference GlobeNewswire -8.07%
Nov-15-21 04:00PM	Surrozen Reports Third Quarter 2021 Financial Results GlobeNewswire -9.01%
08:00AM	Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference GlobeNewswire
08:00AM	Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the Annual Meeting of the American Association for the Study of Liver Diseases GlobeNewswire
Nov-11-21 10:51AM	How Many Surrozen, Inc. (NASDAQ:SRZN) Shares Do Institutions Own? Simply Wall St. +34.57%
Nov-05-21 08:00AM	Surrozen to Present at The Stifel 2021 Virtual Healthcare Conference GlobeNewswire +20.43%
Oct-05-21 04:30PM	Surrozen Presented Data Supporting Potential of SZN-1326 at the 2021 United European Gastroenterology Week GlobeNewswire +7.38%
Sep-23-21 08:30AM	Surrozen Announces Appointment of Liz Nguyen as Vice President and Head of Human Resources GlobeNewswire +16.27%
Aug-11-21 05:30PM	Surrozen Debuts as Publicly Traded Leader in Wnt Biology and Tissue Regeneration GlobeNewswire

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies to engage the body's existing biological repair mechanisms with potential application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 that stimulates hepatocyte regeneration, improves liver function, and reduces fibrosis; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are highly expressed in intestinal crypts. The company was founded in 2016 and is headquartered in South San Francisco, California.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience